23.09
price up icon5.24%   1.15
after-market Dopo l'orario di chiusura: 23.11 0.02 +0.09%
loading
Precedente Chiudi:
$21.94
Aprire:
$23.055
Volume 24 ore:
76,473
Relative Volume:
0.35
Capitalizzazione di mercato:
$329.31M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+2.44%
1M Prestazione:
+34.09%
6M Prestazione:
+48.20%
1 anno Prestazione:
-46.34%
Intervallo 1D:
Value
$22.79
$23.48
Intervallo di 1 settimana:
Value
$20.80
$23.50
Portata 52W:
Value
$6.875
$74.49

Neurogene Inc Stock (NGNE) Company Profile

Name
Nome
Neurogene Inc
Name
Telefono
(877) 237-5020
Name
Indirizzo
535 W 24TH STREET, NEW YORK
Name
Dipendente
107
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
NGNE's Discussions on Twitter

Confronta NGNE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NGNE
Neurogene Inc
23.09 312.91M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-17 Iniziato Craig Hallum Buy
2025-05-16 Downgrade Robert W. Baird Outperform → Neutral
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-06-11 Iniziato Robert W. Baird Outperform
2024-04-29 Iniziato Leerink Partners Outperform
2024-03-21 Iniziato William Blair Outperform
2024-01-08 Iniziato H.C. Wainwright Buy
2024-01-05 Iniziato Stifel Buy
2024-01-04 Iniziato TD Cowen Outperform
Mostra tutto

Neurogene Inc Borsa (NGNE) Ultime notizie

pulisher
Jul 23, 2025

Is Neurogene Inc. a good long term investmentHigh-yield portfolio picks - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Neurogene Inc. stock priceMarket-crushing profits - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Neurogene Inc. Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What makes Neurogene Inc. stock price move sharplyReal Time Stock Signal - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Neurogene Inc. stockFree Market Dynamics Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

how neurogene inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

How Neurogene Inc. stock performs during market volatilityHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Neurogene Inc. stock attracts strong analyst attentionFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Neurogene announces inducement grants - Medical Buyer

Jul 05, 2025
pulisher
Jul 03, 2025

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 03, 2025
pulisher
Jul 03, 2025

Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 03, 2025
pulisher
Jul 01, 2025

Neurogene jumps as FDA approves rare gene therapy trial design - TradingView

Jul 01, 2025
pulisher
Jul 01, 2025

Stifel reiterates Buy rating on Neurogene stock, backs pivotal trial design - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

FDA approves Neurogene’s Rett syndrome gene therapy registrational trial design - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire

Jun 30, 2025
pulisher
Jun 30, 2025

Neurogene Inc.(NasdaqGM: NGNE) dropped from Russell 3000E Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 18, 2025

Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 14, 2025

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks

Jun 12, 2025

Neurogene Inc Azioni (NGNE) Dati Finanziari

Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):